Clinical trials: Chronic Schizophrenia
Schizophrenia
A Safety and PK Study of Injectable Risperidone-SABER and the DosePro Delivery System in Patients With Schizophrenia
This is a Phase 1, open-label study to evaluate the safety and pharmacokinetics (PK) of three doses of risperidone-SABER, administered with a needle and syringe or via the DosePro Needle-Free Delivery System in patients with…
- Trial name
- NCT01592110
- Testing
- risperidone-SABER, ZX003:risperidone-SABER and the DosePro System
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Zogenix, Inc.
Schizophrenia Disorders
Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia
This PoC study is designed to assess the cognitive effects of doses of AQW051 in patients with chronic stable schizophrenia.
- Trial name
- NCT01163227
- Testing
- AQW051 2 mg (single and multiple doses), AQW051 15mg (single and multiple doses), AQW051 100mg (single dose), and 50mg (multiple doses)
- Where
- 2 sites in United States
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Schizophrenia, Impaired Cognition
A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
This study is being conducted to further investigate the safety of prolonged exposure to EVP-6124 in subjects with Schizophrenia receiving a stable dose of an atypical antipsychotic who completed double-blind treatment on studies…
- Trial name
- NCT01714713
- Testing
- EVP-6124
- Where
- 128 sites in United States, Argentina and 14 more
- Volunteers
- 830 people
- Sponsor
- FORUM Pharmaceuticals Inc
Schizophrenia
A Study Comparing the Safety and Efficacy of Ziprasidone and Risperidone for the Treatment of Chronic Schizophrenia
The purpose of this study is to compare the safety of ziprasidone and risperidone for the treatment of chronic schizophrenia. The primary purpose is to differentiate the effects of ziprasidone and risperidone on extrapyramidal…
- Trial name
- NCT00645515
- Testing
- Ziprasidone, Risperidone
- Where
- 3 sites in Spain
- Volunteers
- 240 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Psychotic Disorders, Schizophrenia
Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With Schizophrenia
The purpose of this study is to explore the pharmacokinetics, safety and tolerability of a 4-week long-acting injectable (LAI) formulation of risperidone after single intramuscular (i.m.) injection of 75 mg risperidone LAI in the…
- Trial name
- NCT00821600
- Testing
- risperidone IR and LAI formulation
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Pharmacodynamic/Pharmacokinetic Study of AQW051 in Schizophrenia
Part 1 of the study will assess the enhancement of task-related brain activation (BOLD response) in key brain areas in schizophrenia during the performance of working memory, episodic memory and visual activation tasks as…
- Trial name
- NCT00825539
- Testing
- AQW051
- Where
- 7 sites in United States
- Volunteers
- 68 people
- Sponsor
- Novartis Pharmaceuticals
Schizophrenia
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
This is a study in chronic stable Schizophrenia with the purpose to answer the question of whether agonism of the nicotinic alpha7 receptor is capable of enhancing cognition in a well defined chronic stable patient population…
- Trial name
- NCT01730768
- Testing
- AQW051
- Where
- 13 sites in United States
- Volunteers
- 147 people
- Sponsor
- Novartis Pharmaceuticals
Schizophrenia, Central Nervous System Diseases
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
This study is being conducted to determine the safety and effect on cognitive function of two different doses of an investigational medication, EVP-6124, in individuals with schizophrenia who are on chronic stable atypical…
- Conditions
- Schizophrenia, Central Nervous System Diseases, Cognition
- Trial name
- NCT00968851
- Testing
- EVP-6124
- Where
- 31 sites in United States, Russia and 2 more
- Volunteers
- 317 people
- Sponsor
- FORUM Pharmaceuticals Inc
Schizophrenia, Psychotic Disorders
A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol and Placebo in Patients With Chronic Schizophrenia
The purpose of the study is to evaluate the effectiveness and safety of different doses of risperidone (an antipsychotic medication) compared with placebo and with a fixed 20 mg/day dose of a standard antipsychotic, haloperidol…
- Trial name
- NCT00249132
- Testing
- risperidone
- Volunteers
- 523 people
- Sponsor
- Janssen, LP
Chronic Schizophrenia
Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia
Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe as compared with quetiapine XR long term…
- Trial name
- PEARL 3 Ext (NCT00789698)
- Testing
- Lurasidone HC1, Quetiapine XR
- Where
- 65 sites in United States, Colombia and 4 more
- Volunteers
- 240 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia, Psychotic Disorders
A Comparison of the Effectiveness and Safety of Injectable Risperidone With That of Risperidone Tablets in the Treatment of Patients With Chronic Schizophrenia
The primary purpose of the study is to show that treatment with an injectable formulation of risperidone is not less effective than and has a similar safety profile to risperidone tablets in patients with chronic schizophrenia.
- Trial name
- NCT00249223
- Testing
- Risperidone Long acting injectable
- Volunteers
- 641 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Schizophrenia
SWitching to Abilify Trial (SWAT)
To evaluate the efficacy, safety and tolerance of an 12 and 26-week aripiprazole administration
- Trial name
- NCT00304616
- Testing
- Aripiprazole, Solian, Olanzapine, Seroquel, Risperidone
- Where
- South Korea
- Volunteers
- 500 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Schizophrenia, Psychotic Disorder
A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol in Patients With Chronic Schizophrenia
The purpose of the study is to evaluate the effectiveness and safety of different doses of risperidone (an antipsychotic medication) compared with a fixed 10-mg dose of a standard antipsychotic, haloperidol, in patients with…
- Trial name
- NCT00249119
- Testing
- risperidone
- Volunteers
- 1,579 people
- Sponsor
- Janssen, LP
Schizophrenia, Impaired Cognition
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
The purpose of this study is to determine if EVP-6124 (an alpha-7 nAChR agonist) enhances the cognitive abilities of subjects with Schizophrenia who are also taking stable antipsychotic therapy.
- Trial name
- NCT01714661
- Testing
- EVP-6124
- Where
- 94 sites in United States, Argentina and 11 more
- Volunteers
- 753 people
- Sponsor
- FORUM Pharmaceuticals Inc
Schizophrenia, Schizoaffective Disorder
Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia
This is an open-label, multiple dose, PK and safety study in patients with chronic, stable schizophrenia or schizoaffective disorder.
- Trial name
- NCT02411526
- Testing
- ZX003 (Risperidone-SABER®), Risperdal Consta, Oral Risperidone
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Zogenix, Inc.
Schizophrenia
A Follow-on Study of the Long-Term Safety of Aripiprazole in Patients With Chronic Schizophrenia
The primary objective of the study was to determine the safety of aripiprazole administered long-term in doses ranging from 10 to 30 mg per day as a maintenance therapy in subjects with chronic or first episode of schizophrenia.
- Trial name
- NCT02435836
- Testing
- Aripiprazole
- Volunteers
- 631 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A Study of Cariprazine in Patients With Chronic Stable Schizophrenia
This is an outpatient study to evaluate the long-term safety, tolerability, and pharmacokinetics of cariprazine in patients with schizophrenia.
- Trial name
- NCT00839852
- Testing
- Cariprazine
- Where
- 65 sites in United States, India and 3 more
- Volunteers
- 97 people
- Sponsor
- Forest Laboratories
Schizophrenia
Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia
This 4-week study will evaluate the safety, tolerability and preliminary evidence of efficacy of evenamide (7.5,and 15 mg and placebo, bid) treatment in outpatients with chronic schizophrenia.
- Trial name
- NCT04461119
- Testing
- Evenamide
- Where
- 14 sites in United States, India
- Volunteers
- 138 people
- Sponsor
- Newron Pharmaceuticals SPA
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Schizophrenia
Efficacy Study on Cognitive Functions in Schizophrenic Patients
Primary objectives To compare neurocognitive effects of amisulpride with those of risperidone in patients with chronic schizophrenia, as assessed by the general cognitive index, a measure of overall cognitive functioning in…
- Trial name
- AMIMIND (NCT00761670)
- Testing
- amisulpride and risperidone
- Where
- Hungary
- Volunteers
- 37 people
- Sponsor
- Sanofi